Positive change Positive c	Policy #	Policy Name	Type of Change	Brief Description of Policy Change	Reason for Changes
Author A	NEW	Epkinly (epcoritamab-bysp)	Positive change	DLBCL: remove prior transplant trial criteria. Epkinly will be used following 2 systemic therapies as per FDA labeling.	FDA labeling
MONC 1220 (Indian (emidepain) No clinical change N/A No. (Indian Cha	UM ONC_1227	7 Zolinza (vorinostat)	Positive change		Compendia Listing
MA No. Clinical change	UM ONC_1228	Xtandi (enzalutamide)	No clinical change	N/A	N/A
MA MONC_1263 Keytruda (pembrolizumab) Modificial change Modification orderials Leadment and construction of property in a political change Modification orderials Leadment and construction or property or radiation when used in combination with lemvatibility for political change Modification orderials Leadment and criteria to restrict use of PD-11 inhibitors following progression on TKI for EGFR-mutated metastatic obsease. Leadment and criteria to restrict use of PD-11 inhibitors following progression on TKI for EGFR-mutated metastatic obsease. Leadment and criteria to restrict use of PD-11 inhibitors following progression on TKI for EGFR-mutated metastatic oncaquamous MSCLC. KEYNOTE-789 is still an abstract, wait until article is published. Mod Modification orderials Leadment and criterials resource Modification orderials Leadment and criterials resource Modification orderials Leadment and criterials Modification orderials Leadment and criterials Leadment and criterials Leadment and criterials Modification orderials Leadment and criterials Leadment and criterials Leadment and criterials Leadment and criterials Modification and criterials Leadment and criterials	UM ONC_1230	O Istodax (romidepsin)	No clinical change	N/A	N/A
UM ONC_1263 Keytruda (pembrolizumab) Positive change Positive change (Inclusion criteria: 1. Endometrial cancer: 1. remove criteria for prior surgery or radiation when used in combination with lenvalptib for recurrent/metastatic disease. 2. Add off label use in combination with carboplatin + paclitaxel as first line therapy for recurrent/metastatic disease. 2. Cancer: 1. Endometrial cancer: 1. Endometria: 1. En	UM ONC_1245	Xofigo (radium Ra 223 dichloride)	No clinical change	N/A	N/A
L. Endometrial cancer: 1. remove criteria for prior surgery or radiation when used in combination with lerevalatin by MS stable disease. 2. Action of Industrial consequence of Control of	UM ONC_1248	3 Ixempra (ixabepilone)	No clinical change	N/A	N/A
UM ONC_1277 Alecensa (Alectinib) No clinical change N/A UM ONC_1287 Lenvima (lenvatinib) Positive change in Unusion criteria: 1. Thyroid cancer: do not add preferred and nonpreferred Tki for DTC. 2. Endometrial cancer: remove criteria for prior surgery or radiation. FDA labeling UM ONC_1287 Vescarta (axicabagene ciloleucel) No clinical change N/A N/A UM ONC_1332 Lutathera (Lutetium Lu 177 dotatete) Positive change N/A N/A UM ONC_1332 Lutathera (Lutetium Lu 177 dotatete) No clinical change N/A N/A UM ONC_1332 Virakiv (Irortectinib) No clinical change N/A N/A UM ONC_1333 Cablivi (caplacizumab-yhdp) No clinical change N/A N/A UM ONC_1333 Cablivi (caplacizumab-yhdp) No clinical change N/A N/A UM ONC_1334 Oburismo (glasdegib) No clinical change N/A N/A UM ONC_1345 Nubega (darolutamide) No clinical change N/A N/A UM ONC_1357 Rozlytrek (entrectinib) No clinical change N/A N/A UM ONC_1368 Ro	UM ONC_1263	3 Keytruda (pembrolizumab)	Positive change	 Endometrial cancer: 1. remove critieria for prior surgery or radiation when used in combination with lenvatinib for MSI stable disease. Add off label use in combination with carboplatin + paclitaxel as first line therapy for recurrent/metastatic disease. NSCLC: do not add criteria to restrict use of PD-L1 inhbitors following progression on TKI for EGFR-mutated 	FDA labeling
UM ONC_1328 I Lenvima (lenvatinib) Positive change inclusion criteria: 1. Thyroid cancer: do not add preferred and nonpreferred TKI for DTC. 2. Endometrial cancer: remove criteria for prior surgery or radiation. UM ONC_1329 Yescarta (axicabtagene ciloleucel) MO ONC_1329 Vitrakvi (larotrectinib) Positive change inclusion criteria: remove 4 dose limit Positive change Positive c	UM ONC_1273	3 Lynparza (olaparib)	No clinical change		Clinical trial analysis/criteria
L. Thyroid cancer: do not add preferred and nonpreferred TKI for DTC. 2. Endometrial cancer: remove criteria for prior surgery or radiation. UM ONC_1329 Yescarta (axicabtagene ciloleucel) No clinical change N/A UM ONC_1329 Vescarta (axicabtagene ciloleucel) No clinical change N/A UM ONC_1320 Vitrakvi (Iarotectinib) No clinical change N/A UM ONC_1320 Vitrakvi (Iarotectinib) No clinical change N/A UM ONC_1321 Xospata (Gilteritinib) No clinical change N/A UM ONC_1325 Xospata (Gilteritinib) No clinical change N/A UM ONC_1326 Vitrakvi (Iarotectinib) No clinical change N/A UM ONC_1327 Abject (Iarotectinib) No clinical change N/A UM ONC_1328 Vitrakvi (Iarotectinib) No clinical change N/A UM ONC_1329 Abject (Iarotectinib) No clinical change N/A UM ONC_1329	UM ONC_1277	7 Alecensa (Alectinib)	No clinical change	N/A	N/A
UM ONC_1329 Yescarta (axicabtagene ciloleucel) No clinical change M/A Scalutathera (Lutetium Lu 177 dotatete) Mo clinical change M/A No clinical change M/A No clinical change M/A No clinical change M/A UM ONC_1350 Vitrakvi (larotrectinib) No clinical change M/A No clinical change Inclusion criteria: remove use as a single agent (may be used with low dose cytarabine) for r/r AML Exclusion criteria: remove use as a single agent (may be used with low dose cytarabine) for r/r AML Exclusion criteria: remove criteria for concurrent use of other anticancer therapies. M/A UM ONC_1353 Cablivi (caplacizumab-yhdp) No clinical change N/A No clinical change N/A N/A UM ONC_1354 Daurismo (glasdegib) No clinical change N/A N/A UM ONC_1363 Nubeqa (darolutamide) No clinical change N/A UM ONC_1367 Rozlytrek (entrectinib) No clinical change N/A UM ONC_1377 Brukinsa (zanubrutinib) No clinical change N/A No clinical change N/A UM ONC_1378 Ayvakit (avapritinib) Positive change adults with indolent systemic mastocytosis (iSM), marking the first drug to be specifically approved to treat the disease. N/A N/A N/A	UM ONC_1283	3 Lenvima (lenvatinib)	Positive change	1. Thyroid cancer: do not add preferred and nonpreferred TKI for DTC.	FDA labeling
UM ONC_1352 Lutathera (Lutetium Lu 177 dotatete) Positive change Exclusion criteria: remove 4 dose limit N/A UM ONC_1353 Vitrakvi (larotrectinib) No clinical change N/A Inclusion criteria: remove use as a single agent (may be used with low dose cytarabine) for r/r AML Exclusion criteria: remove use as a single agent (may be used with low dose cytarabine) for r/r AML Exclusion criteria: remove criteria for concurrent use of other anticancer therapies. UM ONC_1353 Cablivi (caplacizumab-yhdp) No clinical change N/A No Clinical change N/A UM ONC_1354 Daurismo (glasdegib) No clinical change N/A UM ONC_1367 Rozlytrek (entrectinib) No clinical change N/A No clinical change N/A UM ONC_1367 Rozlytrek (entrectinib) No clinical change N/A UM ONC_1378 Ayvakit (avapritinib) No clinical change N/A UM ONC_1378 Gamifant (emapalumab-lzsg) No clinical change N/A No clinical change N/A N/A N/A N/A N/A N/A N/A N/A	UM ONC_1310	Wisqali (ribociclib)	No clinical change	Table review of adjuvant ribociclib (NATALEE trial) for September OSAB	Clinical trial analysis/criteria
UM ONC_1350 Vitrakvi (larotrectinib) No clinical change N/A UM ONC_1351 Xospata (Gilteritinib) Positive change Inclusion criteria: remove use as a single agent (may be used with low dose cytarabine) for r/r AML Exclusion criteria: remove criteria for concurrent use of other anticancer therapies. FDA labeling UM ONC_1353 Cablivi (caplacizumab-yhdp) No clinical change N/A N/A UM ONC_1354 Daurismo (glasdegib) No clinical change N/A N/A UM ONC_1363 Nubeqa (darolutamide) No clinical change N/A N/A UM ONC_1367 Rozlytrek (entrectinib) No clinical change N/A N/A UM ONC_1377 Brukinsa (zanubrutinib) No clinical change N/A N/A UM ONC_1378 Ayvakit (avapritinib) Positive change On May 23, 2023, the U.S. Food and Drug Administration (FDA) has approved avapritinib (Ayvakit) for the treatment of adults with indolent systemic mastocytosis (ISM), marking the first drug to be specifically approved to treat the disease. UM ONC_1380 Gamifant (emapalumab-Izsg) No clinical change N/A	UM ONC_1329	Yescarta (axicabtagene ciloleucel)	No clinical change	N/A	N/A
UM ONC_1350 Vitrakvi (larotrectinib) No clinical change N/A UM ONC_1351 Xospata (Gilteritinib) Positive change Inclusion criteria: remove use as a single agent (may be used with low dose cytarabine) for r/r AML Exclusion criteria: remove criteria for concurrent use of other anticancer therapies. FDA labeling UM ONC_1353 Cablivi (caplacizumab-yhdp) No clinical change N/A N/A UM ONC_1354 Daurismo (glasdegib) No clinical change N/A N/A UM ONC_1363 Nubeqa (darolutamide) No clinical change N/A N/A UM ONC_1367 Rozlytrek (entrectinib) No clinical change N/A N/A UM ONC_1377 Brukinsa (zanubrutinib) No clinical change N/A N/A UM ONC_1378 Ayvakit (avapritinib) Positive change On May 23, 2023, the U.S. Food and Drug Administration (FDA) has approved avapritinib (Ayvakit) for the treatment of adults with indolent systemic mastocytosis (ISM), marking the first drug to be specifically approved to treat the disease. UM ONC_1380 Gamifant (emapalumab-Izsg) No clinical change N/A	UM ONC 1332	Lutathera (Lutetium Lu 177 dotatete)	Positive change	Exclusion criteria: remove 4 dose limit	FDA labeling
Land ONC_1353Cablivi (caplacizumab-yhdp)No clinical change N/AN/AUM ONC_1354Daurismo (glasdegib)No clinical change N/AN/AUM ONC_1363Nubeqa (darolutamide)No clinical change N/AN/AUM ONC_1367Rozlytrek (entrectinib)No clinical change N/AN/AUM ONC_1377Brukinsa (zanubrutinib)No clinical change N/AN/AUM ONC_1378Ayvakit (avapritinib)No clinical change N/AN/AUM ONC_1378Ayvakit (avapritinib)Positive change adults with indolent systemic mastocytosis (ISM), marking the first drug to be specifically approved to treat the disease.FDA labeling N/AUM ONC_1380Gamifant (emapalumab-lzsg)N/AN/A		· ·			ÿ
UM ONC_1353 Cablivi (caplacizumab-yhdp) No clinical change N/A UM ONC_1354 Daurismo (glasdegib) No clinical change N/A UM ONC_1363 Nubeqa (darolutamide) No clinical change N/A UM ONC_1367 Rozlytrek (entrectinib) No clinical change N/A UM ONC_1377 Brukinsa (zanubrutinib) No clinical change N/A UM ONC_1378 Ayvakit (avapritinib) Positive change On May 23, 2023, the U.S. Food and Drug Administration (FDA) has approved avapritinib (Ayvakit) for the treatment of adults with indolent systemic mastocytosis (ISM), marking the first drug to be specifically approved to treat the disease. FDA labeling UM ONC_1380 Gamifant (emapalumab-Izsg) No clinical change N/A	UM ONC_1351	1 Xospata (Gilteritinib)	Positive change		FDA labeling
UM ONC_1363 Nubeqa (darolutamide) No clinical change N/A N/A UM ONC_1367 Rozlytrek (entrectinib) No clinical change N/A N/A UM ONC_1377 Brukinsa (zanubrutinib) No clinical change N/A N/A UM ONC_1378 Ayvakit (avapritinib) Positive change On May 23, 2023, the U.S. Food and Drug Administration (FDA) has approved avapritinib (Ayvakit) for the treatment of adults with indolent systemic mastocytosis (ISM), marking the first drug to be specifically approved to treat the disease. UM ONC_1380 Gamifant (emapalumab-lzsg) No clinical change N/A N/A	UM ONC_1353	Cablivi (caplacizumab-yhdp)	No clinical change		N/A
UM ONC_1367Rozlytrek (entrectinib)No clinical changeN/AUM ONC_1377Brukinsa (zanubrutinib)No clinical changeN/AUM ONC_1378Ayvakit (avapritinib)Positive changeOn May 23, 2023, the U.S. Food and Drug Administration (FDA) has approved avapritinib (Ayvakit) for the treatment of adults with indolent systemic mastocytosis (ISM), marking the first drug to be specifically approved to treat the disease.FDA labelingUM ONC_1380Gamifant (emapalumab-Izsg)No clinical changeN/A	UM ONC_1354	4 Daurismo (glasdegib)	No clinical change	N/A	N/A
UM ONC_1377Brukinsa (zanubrutinib)No clinical changeN/AUM ONC_1378Ayvakit (avapritinib)Positive changeOn May 23, 2023, the U.S. Food and Drug Administration (FDA) has approved avapritinib (Ayvakit) for the treatment of adults with indolent systemic mastocytosis (ISM), marking the first drug to be specifically approved to treat the disease.FDA labelingUM ONC_1380Gamifant (emapalumab-lzsg)No clinical changeN/A	UM ONC_1363	Nubeqa (darolutamide)	No clinical change	N/A	N/A
UM ONC_1378 Ayvakit (avapritinib) Positive change On May 23, 2023, the U.S. Food and Drug Administration (FDA) has approved avapritinib (Ayvakit) for the treatment of adults with indolent systemic mastocytosis (ISM), marking the first drug to be specifically approved to treat the disease. UM ONC_1380 Gamifant (emapalumab-lzsg) No clinical change N/A N/A	UM ONC_1367	Rozlytrek (entrectinib)	No clinical change	N/A	N/A
adults with indolent systemic mastocytosis (ISM), marking the first drug to be specifically approved to treat the disease. UM ONC_1380 Gamifant (emapalumab-lzsg) No clinical change N/A N/A	UM ONC_1377	7 Brukinsa (zanubrutinib)	No clinical change	N/A	N/A
	UM ONC_1378	Ayvakit (avapritinib)	Positive change		FDA labeling
UM ONC_1381 Padcev (enfortumab vedotin-ejfv) No clinical change Discussion prepared for UMC FDA labeling	UM ONC_1380	Gamifant (emapalumab-lzsg)	No clinical change	N/A	N/A
	UM ONC_1381	Padcev (enfortumab vedotin-ejfv)	No clinical change	Discussion prepared for UMC	FDA labeling

UM ONC_1383	Sylvant (siltuximab)	No clinical change	N/A	N/A
UM ONC_1387	Unituxin (dinutuximab)	Positive change	Inclusion criteria for neuroblastoma: remove the following criteria 1. Age less than 18 years of age 2. The member had at least a partial response to induction chemotherapy followed by autologous stem cell transplant (ASCT) and radiotherapy 3. Unituxin (dinutuximab) is being used in combination with 13-cis-retinoic acid (isotretinoin), with or without granulocyte-macrophage colony-stimulating factor (sargramostim) or interleukin-2 (aldesleukin).	FDA labeling
UM ONC_1392	Reblozyl (luspatercept-aamt)	No clinical change	Table for September OSAB before we add recommendations from the COMMANDS trial.	Clinical trial analysis/criteria
UM ONC 1396	Koselugo (selumetinib)	Positive change	Remove restriction to pediatric members 2 to 17 years of age with Plexiform Neurofibromas (PN)	FDA labeling
UM ONC_1398	Pemazyre (pemigatinib)	No clinical change	N/A	N/A
UM ONC_1413	Tecartus (brexucabtagene autoleucel)	No clinical change	N/A	N/A
UM ONC_1421	Breyanzi (lisocabtagene maraleucel)	Positive change	Add all 3 FDA labeled indicatons a.Refractory disease to first line chemoimmunotherapy or relapse within 12 months of first line chemoimmunotherapy OR b.Refractory disease to first line chemoimmunotherapy or relapse after first line chemoimmunotherapy AND are not eligible for hematopoietic stem cell transplantation (HSCT) due to comorbidities or age OR c.For chemotherapy-refractory disease after 2 or more lines of systemic chemotherapy.	FDA labeling
UM ONC_1440	Lumakras (sotorasib)	No clinical change	N/A	N/A
UM ONC_1447	Exkivity (mobocertinib)	No clinical change	N/A	N/A
UM ONC_1449	Tivdak (tisotumab vedotin-tftv)	No clinical change	N/A	N/A